Journal of International Psychiatry

Objective: To investigate the clinical efficacy and safety of zopiclone in the treatment of sleep disorders in schizophrenia. Methods: A total of 102 patients with schizophrenia and sleep disorders admitted to our hospital from July 2016 to July 2019 were randomly divided into observation group (51 cases) (zopiclone ) and control group (51 cases)（clonazepam ), compare the PSQI score, treatment efficiency, and incidence of adverse reactions in two groups of patients with schizophrenia. Results: At the end of treatment, the PSQI score (5.24±0.59) and the incidence of adverse reactions (7.84%) were lower in the observation group than in the control group (P<0.05). The effective rate of treatment in the observation group (98.04%) was high. In the control group (84.31%) and the difference was significant (P <0.05). Conclusion: Zopiclone can effectively improve the clinical efficacy of patients with schizophrenia and sleep disorders, reduce its adverse reactions and improve its sleep quality, which is worthy of popularization.

safety; clinical efficacy; schizophrenia; sleep disorders; zopiclone